Company news

Altimmune, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Altimmune to Host Virtual R&D Day on March 13, 2025

March 6, 2025

Altimmune to Participate in the Leerink Global Healthcare Conference

March 3, 2025

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

February 27, 2025

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

February 25, 2025

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

February 20, 2025

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

January 28, 2025

Altimmune Added to Nasdaq Biotechnology Index

December 18, 2024

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

December 1, 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

November 14, 2024

Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update

November 11, 2024

Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer

November 10, 2024

Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2024

Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity

November 6, 2024

Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024

November 3, 2024

Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting® 2024

October 14, 2024

Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference

September 30, 2024

Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

September 29, 2024

Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes

September 9, 2024

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes

September 2, 2024

Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update

August 7, 2024

Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

July 31, 2024

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

July 24, 2024

Altimmune to Participate at Leerink Partners Therapeutics Forum

July 1, 2024

Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt

June 25, 2024

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

June 22, 2024

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions

June 21, 2024

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

June 19, 2024

Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions

June 17, 2024

Altimmune Presents Data at EASL International Liver Congress™ 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH)

June 4, 2024

Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress™ 2024

May 28, 2024

Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update

May 8, 2024

Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024

May 1, 2024

Altimmune to Participate at Two Upcoming Conferences

April 30, 2024

Altimmune Statement on the Passing of Dr. Stephen Harrison

April 24, 2024

Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results

March 26, 2024

Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024

March 19, 2024

Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024

January 1, 2024

Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

November 29, 2023

Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update

November 6, 2023

Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023

October 30, 2023

Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH)

October 25, 2023

Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting® 2023

October 24, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes

September 25, 2023

Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight

September 11, 2023

Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update

August 9, 2023

Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023

August 2, 2023

Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH)

July 31, 2023

Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023

June 15, 2023

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress™ 2023

June 14, 2023

Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update

May 10, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 27 decks. Every deck is listed under its year.